Brinkhaus Benno, Hentschel Christian, Von Keudell Christoph, Schindler Gernot, Lindner Martin, Stützer Hartmut, Kohnen Ralf, Willich Stefan N, Lehmacher Walter, Hahn Eckhart G G
Institute of Social Medicine, Epidemiology, and Health Economics, Charité University Medical Center, Luisenstr. 57, DE-10098 Berlin, Germany.
Scand J Gastroenterol. 2005 Aug;40(8):936-43. doi: 10.1080/00365520510023134.
OBJECTIVE: Irritable bowel syndrome (IBS) is a common functional disorder for which there is no reliable medical treatment. The aim of this study was to determine the efficacy of two herbal remedies used in the treatment of IBS. MATERIAL AND METHODS: In a randomized, double-blind, placebo-controlled trial, IBS patients were randomly assigned to one of three treatment groups: 1) Curcuma xanthorriza 60 mg daily (curcuma group) (n=24), 2) Fumaria officinalis 1500 mg daily (fumitory group) (n=24) and 3) placebo (n=58). The study treatment was applied three times a day for 18 weeks. The main outcome parameters were changes in global patient ratings of IBS-related pain and distension on a visual analogue scale (0-50 mm) between baseline and at the end of treatment. Additional outcome parameters included global assessments of changes in IBS symptoms and psychosocial stress caused by IBS. RESULTS: A total of 106 patients (mean age 48+/-12 years, 63% F) were included in the intention-to-treat group. IBS-related pain decreased by -0.9+/-11.5 (mm+/-SD) in the fumitory group, -0.3+/-9.9 in the placebo group and increased by 2.0+/-9.5 in the curcuma group (p=0.81). IBS-related distension decreased by -1.4+/-12.5 in the curcuma group, -2.1+/-9.2 in the placebo group and increased by 0.3+/-9.3 in the fumitory group (p=0.48). Additionally, the global assessment of changes in IBS symptoms and psychological stress due to IBS did not differ significantly among the three treatment groups. CONCLUSIONS: Neither fumitory nor curcuma showed any therapeutic benefit over placebo in patients with IBS. Therefore, the use of these herbs for the treatment of IBS cannot be recommended.
目的:肠易激综合征(IBS)是一种常见的功能性疾病,尚无可靠的药物治疗方法。本研究旨在确定两种用于治疗IBS的草药疗法的疗效。 材料与方法:在一项随机、双盲、安慰剂对照试验中,IBS患者被随机分配到三个治疗组之一:1)每天服用60毫克郁金(郁金组)(n = 24),2)每天服用1500毫克地锦草(地锦草组)(n = 24),3)安慰剂组(n = 58)。研究治疗每天应用3次,持续18周。主要结局参数是治疗开始时与结束时,患者使用视觉模拟量表(0 - 50毫米)对IBS相关疼痛和腹胀进行的总体评分变化。其他结局参数包括对IBS症状变化和IBS引起的心理社会压力的总体评估。 结果:意向性治疗组共纳入106例患者(平均年龄48±12岁,女性占63%)。地锦草组IBS相关疼痛评分下降了 -0.9±11.5(毫米±标准差),安慰剂组下降了 -0.3±9.9,郁金组上升了2.0±9.5(p = 0.81)。郁金组IBS相关腹胀评分下降了 -1.4±12.5,安慰剂组下降了 -2.1±9.2,地锦草组上升了0.3±9.3(p = 0.48)。此外,三个治疗组在IBS症状变化和IBS所致心理压力的总体评估方面无显著差异。 结论:对于IBS患者,地锦草和郁金在治疗上均未显示出优于安慰剂的效果。因此,不推荐使用这些草药治疗IBS。
World J Gastroenterol. 2012-2-21
Aliment Pharmacol Ther. 2005-2-15
Am J Gastroenterol. 2009-10-6
J Clin Med. 2025-3-8
Clin Gastroenterol Hepatol. 2021-8
J Clin Med. 2018-9-22
Electron Physician. 2016-8-25